Gilead Sciences (GILD) Stock Forecast & Price Target

$88.61 +0.21 (+0.24%)

(As of 02:20 PM ET)

Gilead Sciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 25 Analyst Ratings

Sell
0

Hold
11

Buy
14

Based on 25 Wall Street analysts who have issued ratings for Gilead Sciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 25 analysts, 11 have given a hold rating, 11 have given a buy rating, and 3 have given a strong buy rating for GILD.

Consensus Price Target

$94.00
6.08% Upside

According to the 25 analysts' twelve-month price targets for Gilead Sciences, the average price target is $94.00. The highest price target for GILD is $125.00, while the lowest price target for GILD is $69.00. The average price target represents a forecasted upside of 6.08% from the current price of $88.61.

GILD Analyst Ratings Over Time

Type	Current Forecast 11/19/23 to 11/18/24	1 Month Ago 10/20/23 to 10/19/24	3 Months Ago 8/21/23 to 8/20/24	1 Year Ago 11/19/22 to 11/19/23
Strong Buy	3 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	11 Buy rating(s)	10 Buy rating(s)	7 Buy rating(s)	5 Buy rating(s)
Hold	11 Hold rating(s)	10 Hold rating(s)	12 Hold rating(s)	10 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$94.00	$86.37	$81.94	$88.22
Forecasted Upside	6.08% Upside	-0.41% Downside	9.62% Upside	16.93% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Hold	Hold

Forced out of retirement by these trades (Ad)

You know, I never really intended to get in front of a camera and tell folks about a new market paradigm that I discovered. Even though I have a bright and shiny “resume,” I thought I’d left investing behind forever. And I was more than happy to be a stay-at-home dad… But then I discovered Gamma Pockets… and everything changed

Make sure to check out Gamma Pockets HERE while it’s still widely available

GILD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GILD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Gilead Sciences Stock vs. The Competition

Type	Gilead Sciences	Medical Companies	S&P 500
Consensus Rating Score	2.68	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	6.64% Upside	28,454.02% Upside	9.78% Upside
News Sentiment Rating	Positive News See Recent GILD News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/18/2024	Royal Bank of Canada 4 of 5 stars		Boost Target	Sector Perform ➝ Sector Perform	$81.00 ➝ $84.00	-4.75%
11/15/2024	Wolfe Research 3 of 5 stars	A. Hammond Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$110.00	+19.42%
11/14/2024	Citigroup 3 of 5 stars		Initiated Coverage	Buy	$125.00	+34.95%
11/8/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$83.00 ➝ $97.00
11/8/2024	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Okunewitch Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
11/7/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$95.00 ➝ $105.00	+7.81%
Forced out of retirement by these trades (Ad) You know, I never really intended to get in front of a camera and tell folks about a new market paradigm that I discovered. Even though I have a bright and shiny “resume,” I thought I’d left investing behind forever. And I was more than happy to be a stay-at-home dad… But then I discovered Gamma Pockets… and everything changed Make sure to check out Gamma Pockets HERE while it’s still widely available
11/7/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$100.00 ➝ $105.00	+7.98%
11/7/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$80.00 ➝ $95.00	-2.30%
11/7/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$94.00 ➝ $102.00	+4.90%
11/7/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$74.00 ➝ $84.00	-13.48%
11/7/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$84.00 ➝ $95.00	-1.72%
11/7/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Bansal Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$100.00 ➝ $105.00	+8.63%
11/7/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$70.00 ➝ $80.00	-17.24%
11/7/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$95.00 ➝ $105.00	+7.58%
11/7/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Hold
10/21/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Graybosch Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
10/21/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$74.00 ➝ $96.00	+10.70%
10/17/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Breen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$105.00	+21.04%
8/9/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	U. Raffat Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/8/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$93.00	+39.45%
4/26/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$80.00 ➝ $78.00	+19.28%
4/26/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$90.00 ➝ $85.00	+29.99%
4/24/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Reduce ➝ Hold	$69.00	+2.99%
4/17/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$81.00 ➝ $75.00	+12.06%
2/22/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$101.00 ➝ $90.00	+24.76%
11/9/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold	$75.00	-3.72%
9/8/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$88.00 ➝ $95.00	+28.48%
2/10/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$90.00 ➝ $95.00	+11.07%
12/9/2022	DZ Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$90.00	+0.59%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 02:31 PM ET.

Should I Buy Gilead Sciences Stock? GILD Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, November 3, 2024. Please send any questions or comments about these Gilead Sciences pros and cons to contact@marketbeat.com.

Gilead Sciences
Bull Case

Here are some ways that investors could benefit from investing in Gilead Sciences, Inc.:

Gilead Sciences, Inc. is a biopharmaceutical company that focuses on discovering, developing, and commercializing medicines in areas of unmet medical need.
The company offers a range of successful products such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Sunlencs.
Gilead Sciences, Inc. has a strong presence in the United States, Europe, and internationally, providing a diverse market for its products.
The company has a history of innovation and research in the pharmaceutical industry, leading to the development of cutting-edge treatments.
Recent developments in the company have shown promising results, indicating potential growth and profitability for investors.

Gilead Sciences
Bear Case

Investors should be bearish about investing in Gilead Sciences, Inc. for these reasons:

Despite its successes, Gilead Sciences, Inc. faces competition in the biopharmaceutical industry, which could impact its market share and profitability.
The company's stock price has been fluctuating in recent periods, indicating potential volatility in the market.
Changes in regulations and healthcare policies could affect Gilead Sciences, Inc.'s ability to bring new products to market and generate revenue.
Investing in the pharmaceutical industry carries inherent risks related to clinical trials, regulatory approvals, and market acceptance of new treatments.
While Gilead Sciences, Inc. has a strong product portfolio, the company may face challenges in maintaining its competitive edge in a rapidly evolving industry.

GILD Forecast - Frequently Asked Questions

: According to the research reports of 25 Wall Street equities research analysts, the average twelve-month stock price forecast for Gilead Sciences is $94.00, with a high forecast of $125.00 and a low forecast of $69.00.
: 25 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last twelve months. There are currently 11 hold ratings, 11 buy ratings and 3 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GILD shares.
: According to analysts, Gilead Sciences's stock has a predicted upside of 6.08% based on their 12-month stock forecasts.
: Over the previous 90 days, Gilead Sciences's stock had 4 upgrades and 1 downgrade by analysts.
: Gilead Sciences has been rated by research analysts at Barclays, BMO Capital Markets, Cantor Fitzgerald, Citigroup, JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Maxim Group, Needham & Company LLC, Oppenheimer, Piper Sandler, Robert W. Baird, Royal Bank of Canada, Sanford C. Bernstein, The Goldman Sachs Group, Truist Financial, Wells Fargo & Company, and Wolfe Research in the past 90 days.
: Analysts like Gilead Sciences less than other "medical" companies. The consensus rating score for Gilead Sciences is 2.68 while the average consensus rating score for "medical" companies is 2.80. Learn more on how GILD compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Forced out of retirement by these trades (Ad)

Make sure to check out Gamma Pockets HERE while it’s still widely available

This page (NASDAQ:GILD) was last updated on 11/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gilead Sciences (GILD) Stock Forecast & Price Target